# US 2022/0033856 A1 · Methods for increasing fetal hemoglobin content in eukaryotic cells and uses thereof for the treatment of hemoglobinopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033856 A1
- Document ID: US20220033856A1
- Status: Published application
- Kind: A1
- Application number: 17/274,966
- Filed: 2019-09-10
- Published: 2022-02-03
- Earliest claimed: 2018-09-11
- Assignees: Universite De Paris; Assistance Publique-HôPitaux De Paris (Aphp); Fondation Imagine
- Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale); Université de Paris; Assistance Publique-Hôpitaux de Paris (APHP); Fondation Imagine
- Inventors: Annarita MICCIO; Leslie WEBER
- Web page: https://patentgrep.com/patent/US20220033856A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/907: {in mammalian cells}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C07K 14/805: Haemoglobins; Myoglobins
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/30: Special therapeutic applications
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The clinical severity of β-hemoglobinopathies is alleviated by the co-inheritance of genetic mutations causing a sustained fetal γ-globin chain production at adult age, a condition termed hereditary persistence of fetal hemoglobin (HPFH). Here, the inventors have compared the extent of fetal hemoglobin (HbF) de-repression following CRISPR/Cas9-mediated targeting of different regions of the HBG1 and HBG2 promoters in an adult erythroid cell line (HUDEP-2). They achieved a potent and pancellular HbF re-activation upon disruption of binding sites for γ-globin repressors located in both HBG1 and HBG2 genes. They validated these findings in Red Blood Cells (RBCs) derived from genome edited Sickle Cell Disease (SCD) patient hematopoietic stem/progenitor cells. Overall, this study identified a binding site for an HbF repressor as a novel and potent target for the treatment of β-hemoglobinopathies. Accordingly, the present invention relates to a method for increasing fetal hemoglobin content in a eukaryotic cell comprising the step of disrupting the binding site for Leukemia/lymphoma-related factor (LRF) in the HBG1 or HBG2 promoter.

## Claims

### Claim 1

A method for increasing fetal hemoglobin content in a eukaryotic cell comprising the step of disrupting the binding site for Leukemia/lymphoma-related factor (LRF) in the HBG1 or HBG2 promoter.

### Claim 2 (depends on 1)

The method of claim 1 wherein the eukaryotic cell is selected from the group consisting of hematopoietic progenitor cells, hematopoietic stem cells (HSCs), and pluripotent cells.

### Claim 3 (depends on 1)

The method of claim 1 which comprises contacting the eukaryotic cell with an effective amount of a DNA-targeting endonuclease whereby the DNA-targeting endonuclease cleaves the genomic DNA of the cell in at least one position located in or close to the binding site for Leukemia/lymphoma-related factor (LRF) in the HBG1 or HBG2 promoter.

### Claim 4 (depends on 3)

The method of claim 3 wherein the DNA-targeting endonuclease leads to the genome editing of the −200 region in the HBG1 or HBG2 promoter.

### Claim 5 (depends on 3)

The method of claim 3 wherein the DNA targeting endonuclease cleaves the genomic sequence
between positions −198 and −197 in the HBG1 or HBG2 promoter wherein positions −198 and −197 correspond to positions 13 and 14 in SEQ ID NO:1, or
between positions −197 and −196 in the HBG1 or HBG2 wherein positions −197 and −196 correspond to positions 14 and 15 in SEQ ID NO:1, or
between positions −196 and −195 in the HBG1 or HBG2 promoter wherein positions −196 and −195 correspond to positions 15 and 16 in SEQ ID NO:1.

### Claim 6 (depends on 3)

The method of claim 3 wherein the DNA targeting endonuclease is a TALEN or a ZFN.

### Claim 7 (depends on 3)

The method of claim 3 wherein the DNA targeting endonuclease is a CRISPR-associated endonuclease.

### Claim 8 (depends on 7)

The method of claim 7 wherein the CRISPR-associated endonuclease is a Cas9 nuclease or is Cpf1 nuclease or any variant of these nucleases.

### Claim 9 (depends on 7)

The method of claim 7 which comprises the step of contacting the eukaryotic cell with an effective amount of the CRISPR-associated endonuclease and with one or more guide RNAs.

### Claim 10 (depends on 9)

The method of claim 9 wherein the one or more guide RNAs comprises:
the spacer sequence as set forth in SEQ ID NO: 2 (5′ AUUGAGAUAGUGUGGGGAAG 3′) for recruiting the CRISPR-associated endonuclease to the HBG1 and HBG2 promoters and generating double-strand breaks between positions −198 and −197 wherein positions −198 and −197 correspond to positions 13 and 14 in SEQ ID NO:1, or
the spacer sequence as set forth in SEQ ID NO: 3 (5′ CAUUGAGAUAGUGUGGGGAA 3′) for recruiting the CRISPR-associated endonuclease to the HBG1 and HBG2 promoters and generating double-strand breaks between positions −197 and −196 wherein positions −197 and −196 correspond to positions 14 and 15 in SEQ ID NO:1, or
the spacer sequence as set forth in SEQ ID NO: 4 (5′ GCAUUGAGAUAGUGUGGGGA 3′) for recruiting the CRISPR-associated endonuclease to the HBG1 and HBG2 promoters and generating double-strand breaks between positions −195 and −196 wherein positions −195 and −196 correspond to positions 15 and 16 in SEQ ID NO:1.

### Claim 11 (depends on 10)

The method of claim 10 wherein the CRISPR-associated endonuclease is pre-complexed with a guide RNA to form a ribonucleoprotein (RNP) complex.

### Claim 12 (depends on 1)

A method for increasing fetal hemoglobin levels in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a population of eukaryotic cells obtained by the method according to claim 1.

### Claim 13 (depends on 12)

The method of claim 12 wherein the subject suffers from sickle cell disease or β-thalassemia.

### Claim 14

A kit of parts comprising i) a CRISPR-associated endonuclease and ii) a guide RNA that comprises the sequence as set forth in SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.

### Claim 15 (depends on 1)

A method for the treatment of a hemoglobinopathy in a subject in need thereof, comprising, administering to the subject a therapeutically effective amount of a population of eukaryotic cells obtained by the method according to claim 1.

### Claim 16 (depends on 2)

The method of claim 2 wherein the pluripotent cells are embryonic stem cells (ES) or induced pluripotent stem cells (iPS).
